Molecule
Ranibizumab is a vascular endothelial growth factor inhibitor indicated for the treatment of patients with lUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with, among other approved uses. MedsAcross supplies Ranibizumab for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
LUCENTIS is indicated for the treatment of patients with: LUCENTIS, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD). Macular Edema Following Retinal Vein Occlusion (RVO). Diabetic Macular Edema (DME). Diabetic Retinopathy (DR). Myopic Choroidal Neovascularization (mCNV)
Source: US FDA prescribing information
Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.
Source: US FDA prescribing information
For ophthalmic intravitreal injection only. Neovascular (Wet) Age-Related Macular Degeneration (AMD): LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days). - Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. - Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Patients should be assessed regularly. Macular Edema Following Retinal Vein Occlusion (RVO): LUCENTIS 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).
Source: US FDA prescribing information
Ocular or periocular infections. Hypersensitivity Ocular or Periocular Infections LUCENTIS is contraindicated in patients with ocular or periocular infections.
Source: US FDA prescribing information
Endophthalmitis and retinal detachments may occur following intravitreal injections. Patients should be monitored following the injection. Increases in intraocular pressure (IOP) have been noted both pre- and post-intravitreal injection. There is a potential risk of arterial thromboembolic events following intravitreal use of VEGF inhibitors. Fatal events occurred more frequently in patients with DME and DR at baseline, who were treated monthly with LUCENTIS compared with control.
Source: US FDA prescribing information
The following adverse reactions are discussed in greater detail in other sections of the label: Endophthalmitis and Retinal Detachments Increases in Intraocular Pressure Thromboembolic Events Fatal Events in patients with DME and DR at baseline The most common adverse reactions (reported more frequently in LUCENTIS-treated subjects than control subjects) are conjunctival hemorrhage, eye pain, vitreous floaters, and increased IOP.
Source: US FDA prescribing information
Drug interaction studies have not been conducted with LUCENTIS. LUCENTIS intravitreal injection has been used adjunctively with PDT. Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation, in 10 of the 12 patients, this occurred when LUCENTIS was administered 7 days (± 2 days) after PDT.
Source: US FDA prescribing information
LUCENTIS should be refrigerated at 2º-8ºC (36º-46ºF). DO NOT FREEZE. Protect LUCENTIS prefilled syringes from light and store in the original carton until time of use.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
8 presentations of Ranibizumab, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Byooviz 0.5 mg/0.05 mL injectionIntravitreal Cold chain | Biogen | US FDA | Available on request |
| Cimerli 0.3 mg/0.05 mL injectionIntravitreal Cold chain | Sandoz | US FDA | Available on request |
| Cimerli 0.5 mg/0.05 mL injectionIntravitreal Cold chain | Sandoz | US FDA | Available on request |
| Susvimo 100 mg/1 mL injectionIntravitreal Cold chain | Genentech | US FDA | Available on request |
| Lucentis 0.3 mg/0.05 mL injectionIntravitreal Cold chain | Genentech | US FDA | Available on request |
| Lucentis 0.5 mg/0.05 mL injectionIntravitreal Cold chain | Genentech | US FDA | Available on request |
| Nufymco 0.3 mg/0.05 mL injectionIntravitreal Cold chain | Zydus LifesciencesIndia | US FDA | Available on request |
| Nufymco 0.5 mg/0.05 mL injectionIntravitreal Cold chain | Zydus LifesciencesIndia | US FDA | Available on request |
5 brand names across 1 markets.
Indian manufacturers are highlighted.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
Conditions linked to Ranibizumab in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 8 presentations of Ranibizumab and sources them for licensed hospitals, importers and physicians against valid import documents. Indian manufacturers include Zydus Lifesciences.
The catalogue lists 5 brand names for Ranibizumab, including Byooviz, Cimerli, Lucentis, Nufymco, Susvimo.
Yes. The US FDA first approved Ranibizumab on 30 June 2006, according to Drugs@FDA.
Yes. Ranibizumab has a central EU marketing authorisation (status: authorised), according to European Medicines Agency data.
At least one listed presentation of Ranibizumab must be kept cold, so it is shipped in temperature-controlled packaging. Check the storage line on each presentation.
Ranibizumab is classified under ATC code S01LA04 (Bevacizumab).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.